Gilead Sciences, Inc. secured U.S. Food and Drug Administration approval on June 24, 2026, for Trodelvy, or sacituzumab govitecan-hziy, in the first-line treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer. The antibody-drug conjugate can be used alone in patients who are not candidates for PD-1 or PD-L1 inhibitor therapy, or with Keytruda, also known as pembrolizumab, or Keytruda Qlex, comprising pembrolizumab and berahyaluronidase alfa-pmph, in patients whose tumours have a PD-L1 combined positive score of at least 10.
Why Trodelvy’s first-line approval changes the treatment sequence in metastatic TNBC
The most important consequence is that Trodelvy no longer needs to be reserved for patients whose metastatic disease has already progressed through earlier systemic therapies. Moving the drug into the first-line setting gives clinicians the option to expose tumours to a Trop-2-directed antibody-drug conjugate before resistance, cumulative toxicity and declining patient fitness narrow the available treatment choices.
That sequencing change matters particularly in metastatic triple-negative breast cancer because a meaningful proportion of patients never reach a second treatment line. Rapid disease progression, organ involvement and deterioration in performance status can make a theoretically available later-line drug irrelevant in practice. A therapy that produces longer disease control when used at diagnosis of advanced disease may therefore influence more patients than the same therapy used after one or two failed regimens.
The approval does not create a single universal pathway. Treatment selection still depends on PD-L1 testing, previous immunotherapy exposure, contraindications to checkpoint inhibition and broader clinical suitability. The label therefore expands choice while also making the first-line decision more complex, requiring clinicians to determine not only whether Trodelvy is appropriate, but whether it should be used alone or as the cytotoxic component of an immunotherapy combination.
How ASCENT-03 strengthens the case for replacing conventional first-line chemotherapy
The Phase 3 ASCENT-03 trial enrolled 558 patients who had not received systemic therapy for advanced triple-negative breast cancer and were not candidates for PD-1 or PD-L1 inhibitor treatment. Trodelvy produced median progression-free survival of 9.7 months, compared with 6.9 months for physician-selected chemotherapy, representing a 38 percent reduction in the risk of progression or death.
The scale of the progression-free survival improvement is clinically relevant, but the pattern of benefit is equally informative. Confirmed response rates were relatively close, at 50 percent with Trodelvy and 47 percent with chemotherapy. The clearer separation appeared in how long responses lasted, with median duration of response reaching 12.2 months for Trodelvy compared with 7.2 months for chemotherapy.
This suggests that the principal advantage may not be a dramatic increase in the proportion of tumours that initially shrink. Instead, Trodelvy appears capable of sustaining control for longer in patients whose disease responds. For an aggressive cancer in which early treatment failure can rapidly eliminate future options, response durability may be more consequential than a modest difference in the initial response rate.
ASCENT-03 nevertheless leaves important uncertainty. Overall-survival results were immature when the indication was approved, meaning it remains unclear whether delaying progression will ultimately translate into longer survival. The trial also allowed eligible patients in the chemotherapy group to receive Trodelvy after progression, which is clinically appropriate but may reduce the ability of later analyses to demonstrate a clear survival difference between treatment sequences.
Why ASCENT-04 gives Gilead Sciences a broader role in PD-L1-positive disease
For patients with PD-L1-positive tumours, the competitive question was not whether Trodelvy could outperform chemotherapy alone. The relevant standard already included Keytruda combined with chemotherapy, meaning Gilead Sciences needed to show that replacing conventional chemotherapy with the antibody-drug conjugate could improve outcomes without undermining the immunotherapy backbone.
The Phase 3 ASCENT-04/KEYNOTE-D19 trial addressed that question in 443 previously untreated patients with a PD-L1 combined positive score of at least 10. Trodelvy plus Keytruda produced median progression-free survival of 11.2 months, compared with 7.8 months for Keytruda plus physician-selected chemotherapy, reducing the risk of progression or death by 35 percent.
Confirmed response rates were 61 percent with Trodelvy plus Keytruda and 55 percent with Keytruda plus chemotherapy. Median duration of response was 16.5 months and 9.2 months, respectively, reinforcing the same durability signal seen in ASCENT-03. The combination therefore improved disease control against an active immunotherapy-containing comparator rather than against a weak or outdated control regimen.
The result also validates a broader development strategy for antibody-drug conjugates. Instead of functioning only as replacements for chemotherapy after treatment failure, ADCs can potentially become combination backbones that deliver a cytotoxic payload alongside immunotherapy. Gilead Sciences and Merck & Co., Inc. now have regulatory evidence that this approach can outperform checkpoint inhibition paired with conventional chemotherapy in a biomarker-selected first-line population.
However, overall-survival data remain immature in ASCENT-04 as well. Crossover to Trodelvy after progression may further complicate the eventual survival analysis. Clinicians will therefore need to judge whether the established progression-free survival and response-duration benefits justify immediate adoption before definitive survival evidence matures.
What the trials reveal about Trodelvy’s benefits beyond headline response rates
The two studies together suggest that Trodelvy’s first-line value is driven more by sustained tumour control than by a transformative increase in initial response probability. That distinction is important because objective response rate can attract attention while offering an incomplete picture of how long a therapy remains useful.
In both trials, the response-rate differences were smaller than the differences in duration of response and progression-free survival. Trodelvy appears to convert a similar or moderately higher chance of initial response into a more durable period before progression. That profile could reduce the frequency of early treatment changes and postpone exposure to subsequent regimens.
The open-label designs introduce a limitation because investigators and patients knew which treatment had been assigned. Progression was therefore assessed through blinded independent central review, reducing the risk that treatment knowledge influenced the primary endpoint. Even so, open-label treatment can affect dose modifications, supportive care, discontinuation decisions and patient-reported outcomes.
The comparator arms also included several physician-selected chemotherapy options. This reflects routine practice and makes the findings broadly applicable, but it can obscure whether Trodelvy’s advantage is equally strong against every individual regimen. Future analyses will need to clarify outcomes by chemotherapy choice, prior early-stage immunotherapy exposure, metastatic disease pattern and other clinically important subgroups.
Why an ADC-based regimen does not eliminate the cytotoxic treatment burden
Trodelvy is often positioned as an alternative to conventional chemotherapy, but the distinction should not be interpreted as the removal of cytotoxic therapy. Sacituzumab govitecan-hziy delivers SN-38, a topoisomerase I inhibitor payload, through an antibody directed at Trop-2. The delivery mechanism is more targeted than administering conventional chemotherapy systemically, but the treatment retains substantial haematological and gastrointestinal toxicity.
The prescribing information carries a boxed warning for severe neutropenia and diarrhoea. Across the Trodelvy safety database, neutropenia occurred in approximately two-thirds of treated patients, with severe cases remaining common. Diarrhoea, nausea, vomiting, infusion-related reactions and the need for treatment interruptions or dose reductions create a significant supportive-care workload.
In ASCENT-03, the most frequent severe treatment-emergent adverse events included neutropenia and diarrhoea. ASCENT-04 showed a similar pattern when Trodelvy was combined with Keytruda, although treatment discontinuation due to adverse events was lower with the Trodelvy combination than with chemotherapy plus Keytruda.
That discontinuation finding may support real-world acceptance, but it should not be mistaken for a low-toxicity profile. Adoption will depend on whether oncology centres can manage blood-count monitoring, growth-factor prophylaxis for higher-risk patients, diarrhoea management, antiemetic premedication and infusion reactions consistently. Patients with reduced UGT1A1 activity may face greater risks of neutropenia and anaemia, adding another layer to treatment monitoring.
The infusion schedule also remains operationally demanding. Trodelvy is administered intravenously on days one and eight of each 21-day cycle until progression or unacceptable toxicity. This may offer fewer visits than some weekly chemotherapy schedules, but it still requires repeated infusion-centre capacity and cannot match the convenience of an oral therapy.
How reimbursement and treatment economics could influence real-world adoption
The clinical case for earlier Trodelvy use is stronger than it was in later-line disease, but the financial implications are also larger. First-line treatment applies to a broader eligible population and is generally administered for longer than rescue therapy used after multiple relapses. Combining Trodelvy with Keytruda creates a particularly resource-intensive regimen involving two branded oncology products.
Payers are likely to focus on the magnitude and durability of progression-free survival, treatment discontinuation rates, downstream therapy use and the absence of mature overall-survival evidence. A clear FDA label and strong guideline positioning should support coverage, but formularies may still impose biomarker documentation, prior-authorisation requirements or confirmation that a patient is unsuitable for checkpoint inhibition when Trodelvy monotherapy is selected.
The monotherapy indication also raises an interpretive issue because being unsuitable for PD-1 or PD-L1 therapy is broader than simply having a PD-L1-negative tumour. The population can include patients with contraindications, relevant comorbidities or previous checkpoint-inhibitor exposure in curative treatment. Consistent documentation will be important to prevent variation in access between treatment centres and insurance plans.
Manufacturing reliability will become more commercially significant as the eligible population expands. Antibody-drug conjugates require coordinated production of the antibody, linker, cytotoxic payload and finished sterile product. Gilead Sciences already has an established global Trodelvy supply network, but first-line adoption across two patient pathways will test whether capacity can scale without creating treatment delays.
What the FDA decision means for the next phase of antibody-drug conjugate competition
Trodelvy now holds a first-mover advantage among antibody-drug conjugates in first-line metastatic triple-negative breast cancer. The strategic significance extends beyond one indication because the approval provides proof that an ADC can replace conventional chemotherapy both as monotherapy and as the cytotoxic partner in an immunotherapy regimen.
Competing developers will need to show more than activity in heavily pretreated disease. The new benchmark includes randomised evidence against active first-line comparators, durable responses, manageable toxicity and compatibility with checkpoint inhibitors. Demonstrating a higher response rate without longer disease control may no longer be sufficient.
For Gilead Sciences, the expansion also strengthens the case for developing Trodelvy in earlier-stage and potentially curative settings. Success in metastatic first-line disease provides biological and regulatory support for studying the drug before metastatic recurrence, when the objective shifts from controlling disease to preventing it from returning. However, tolerance thresholds will be higher in curative populations, where patients may be exposed to significant toxicity despite having no visible metastatic disease.
The wider Trodelvy programme also carries portfolio risk. Positive results in triple-negative breast cancer do not guarantee equivalent success across hormone receptor-positive breast cancer or other Trop-2-expressing tumours. Differences in tumour biology, treatment history and competing standards can materially alter the performance of the same ADC.
What clinicians, regulators and industry observers will watch after the approval
The most consequential future data will be mature overall survival from ASCENT-03 and ASCENT-04. Progression-free survival is meaningful in an aggressive metastatic cancer, but a survival advantage would more firmly establish Trodelvy-based therapy as the preferred first-line approach and strengthen reimbursement arguments.
Real-world sequencing will be another major focus. Patients who receive Trodelvy first may later become candidates for other topoisomerase I inhibitor ADCs or related therapies. The industry still has limited evidence on cross-resistance between ADCs that use similar payload classes, even when they target different tumour antigens.
Clinicians will also watch whether earlier Trodelvy exposure changes the effectiveness of subsequent chemotherapy, immunotherapy or ADC treatment. The ideal sequence cannot be determined from the first-line trials alone, particularly because crossover blurred the distinction between immediate and delayed Trodelvy use.
The FDA decision gives metastatic triple-negative breast cancer treatment a broader and more durable first-line option across PD-L1 pathways. Its long-term importance will depend on whether the progression-free survival gains translate into longer survival, whether toxicity can be managed outside highly experienced trial centres and whether the cost of extended ADC-based treatment remains acceptable to healthcare systems.
Gilead expands Trodelvy into first-line metastatic TNBC, but survival questions remain unresolved added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →